{"id":69414,"date":"2026-07-06T11:32:32","date_gmt":"2026-07-06T03:32:32","guid":{"rendered":"https:\/\/flcube.com\/?p=69414"},"modified":"2026-07-06T11:32:33","modified_gmt":"2026-07-06T03:32:33","slug":"shaanxi-micot-enrolls-first-patient-in-phase-ib-ii-clinical-trial-of-mt1002-for-acute-ischemic-stroke-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69414","title":{"rendered":"Shaanxi Micot Enrolls First Patient in Phase Ib\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shaanxi Micot Pharmaceutical Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2335:HKG\">HKG: 2335<\/a>) announced the successful enrollment of the first subject in its <strong>Phase Ib\/II clinical trial<\/strong> for <strong>MT1002<\/strong>, an independently developed investigational drug targeting <strong>acute ischemic stroke (AIS)<\/strong>. The milestone marks a critical advancement in addressing one of the leading causes of death and disability worldwide, with significant implications for China&#8217;s aging population and global stroke therapeutics market.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-design-overview\" class=\"wp-block-heading\">Clinical Trial Design Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Study Design<\/th><th>Primary Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Part 1<\/strong><\/td><td>Multicenter clinical study<\/td><td>Safety, efficacy, and pharmacokinetic characteristics of MT1002 in AIS patients<\/td><\/tr><tr><td><strong>Part 2<\/strong><\/td><td>Multicenter, randomized, standard-of-care-controlled study<\/td><td>Safety and efficacy evaluation of MT1002 vs. current standard of care in AIS patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-development-context-amp-market-opportunity\" class=\"wp-block-heading\">Development Context &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Acute Ischemic Stroke Burden:<\/strong> AIS accounts for approximately 87% of all stroke cases globally, with limited therapeutic options beyond the narrow time window for thrombolytic therapy<\/li>\n\n\n\n<li><strong>Current Treatment Gaps:<\/strong> Existing interventions primarily focus on reperfusion strategies, with significant unmet need for neuroprotective agents that can extend the treatment window and improve functional outcomes<\/li>\n\n\n\n<li><strong>Chinese Market Significance:<\/strong> China experiences over 2 million new stroke cases annually, representing the world&#8217;s largest stroke patient population and creating substantial commercial opportunity for effective therapies<\/li>\n\n\n\n<li><strong>Global Competitive Landscape:<\/strong> MT1002 enters a pipeline landscape where recent neuroprotective candidates have faced high attrition rates, highlighting both the challenge and potential reward of successful development<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-shaanxi-micot\" class=\"wp-block-heading\">Strategic Implications for Shaanxi Micot<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> MT1002 represents a strategic expansion beyond the company&#8217;s traditional therapeutic areas into high-impact neurological disorders<\/li>\n\n\n\n<li><strong>Clinical Development Strategy:<\/strong> The integrated Phase Ib\/II design enables efficient dose-finding and preliminary efficacy assessment while generating robust safety data for regulatory submissions<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Successful completion could position MT1002 for expedited review pathways in China and international markets given the significant unmet medical need<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> First-in-class or best-in-class neuroprotective agent for AIS could achieve peak annual sales exceeding $500 million globally, with premium pricing potential in acute care settings<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-development-milestones\" class=\"wp-block-heading\">Next Development Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Recruitment:<\/strong> Target enrollment of [specific number if available] patients across multiple centers in China<\/li>\n\n\n\n<li><strong>Interim Analysis:<\/strong> Planned safety and futility assessments to guide dose selection for Part 2<\/li>\n\n\n\n<li><strong>Primary Endpoint Readout:<\/strong> Expected within 12-18 months based on typical AIS trial timelines<\/li>\n\n\n\n<li><strong>Regulatory Engagement:<\/strong> Ongoing discussions with NMPA and potential parallel engagement with FDA\/EMA for global development strategy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The initiation of patient enrollment in this Phase Ib\/II trial represents a significant de-risking event for MT1002, advancing Shaanxi Micot&#8217;s pipeline into mid-stage clinical development for a condition affecting millions of patients worldwide with limited therapeutic options.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070301972_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026070301972_c.\"><\/object><a id=\"wp-block-file--media-bbc15f71-6211-4f52-b0bb-f1ae083b44cd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070301972_c.pdf\">2026070301972_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070301972_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bbc15f71-6211-4f52-b0bb-f1ae083b44cd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced the successful enrollment of the first&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,4833,4205],"class_list":["post-69414","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-2335","tag-micot"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shaanxi Micot Enrolls First Patient in Phase Ib\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced the successful enrollment of the first subject in its Phase Ib\/II clinical trial for MT1002, an independently developed investigational drug targeting acute ischemic stroke (AIS). The milestone marks a critical advancement in addressing one of the leading causes of death and disability worldwide, with significant implications for China&#039;s aging population and global stroke therapeutics market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69414\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shaanxi Micot Enrolls First Patient in Phase Ib\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment\" \/>\n<meta property=\"og:description\" content=\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced the successful enrollment of the first subject in its Phase Ib\/II clinical trial for MT1002, an independently developed investigational drug targeting acute ischemic stroke (AIS). The milestone marks a critical advancement in addressing one of the leading causes of death and disability worldwide, with significant implications for China&#039;s aging population and global stroke therapeutics market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69414\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-06T03:32:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-06T03:32:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69414#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69414\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shaanxi Micot Enrolls First Patient in Phase Ib\\\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment\",\"datePublished\":\"2026-07-06T03:32:32+00:00\",\"dateModified\":\"2026-07-06T03:32:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69414\"},\"wordCount\":436,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 2335\",\"Micot Pharmaceutical Technology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69414#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69414\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69414\",\"name\":\"Shaanxi Micot Enrolls First Patient in Phase Ib\\\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-06T03:32:32+00:00\",\"dateModified\":\"2026-07-06T03:32:33+00:00\",\"description\":\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced the successful enrollment of the first subject in its Phase Ib\\\/II clinical trial for MT1002, an independently developed investigational drug targeting acute ischemic stroke (AIS). The milestone marks a critical advancement in addressing one of the leading causes of death and disability worldwide, with significant implications for China's aging population and global stroke therapeutics market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69414#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69414\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69414#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shaanxi Micot Enrolls First Patient in Phase Ib\\\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shaanxi Micot Enrolls First Patient in Phase Ib\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced the successful enrollment of the first subject in its Phase Ib\/II clinical trial for MT1002, an independently developed investigational drug targeting acute ischemic stroke (AIS). The milestone marks a critical advancement in addressing one of the leading causes of death and disability worldwide, with significant implications for China's aging population and global stroke therapeutics market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69414","og_locale":"en_US","og_type":"article","og_title":"Shaanxi Micot Enrolls First Patient in Phase Ib\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment","og_description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced the successful enrollment of the first subject in its Phase Ib\/II clinical trial for MT1002, an independently developed investigational drug targeting acute ischemic stroke (AIS). The milestone marks a critical advancement in addressing one of the leading causes of death and disability worldwide, with significant implications for China's aging population and global stroke therapeutics market.","og_url":"https:\/\/flcube.com\/?p=69414","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-06T03:32:32+00:00","article_modified_time":"2026-07-06T03:32:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69414#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69414"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shaanxi Micot Enrolls First Patient in Phase Ib\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment","datePublished":"2026-07-06T03:32:32+00:00","dateModified":"2026-07-06T03:32:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69414"},"wordCount":436,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 2335","Micot Pharmaceutical Technology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69414#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69414","url":"https:\/\/flcube.com\/?p=69414","name":"Shaanxi Micot Enrolls First Patient in Phase Ib\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-06T03:32:32+00:00","dateModified":"2026-07-06T03:32:33+00:00","description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced the successful enrollment of the first subject in its Phase Ib\/II clinical trial for MT1002, an independently developed investigational drug targeting acute ischemic stroke (AIS). The milestone marks a critical advancement in addressing one of the leading causes of death and disability worldwide, with significant implications for China's aging population and global stroke therapeutics market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69414#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69414"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69414#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shaanxi Micot Enrolls First Patient in Phase Ib\/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69414"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69414\/revisions"}],"predecessor-version":[{"id":69416,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69414\/revisions\/69416"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}